Today: The Goldman Sachs Group Inc. Reiterates Sell Rating for Astrazeneca PLC (AZN)

The Goldman Sachs Group Inc. Reiterates Sell Rating for Astrazeneca PLC (AZN)

Astrazeneca PLC (NYSE:AZN)‘s stock had its “sell” rating restated by Goldman Sachs Group Inc. in a research report issued on Wednesday.

A number of other brokerages also recently issued reports on AZN. Shore Capital reaffirmed a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. reaffirmed a “buy” rating and set a $36.65 price target on shares of Astrazeneca PLC in a report on Monday, July 18th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Friday, September 23rd. Berenberg Bank reissued a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Finally, Beaufort Securities reissued a “hold” rating on shares of Astrazeneca PLC in a report on Friday, August 26th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.49.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 32.57 on Wednesday. The company has a market cap of $82.40 billion, a price-to-earnings ratio of 37.22 and a beta of 0.75. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04. The stock has a 50 day moving average of $33.33 and a 200 day moving average of $30.74.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. During the same period in the prior year, the firm posted $1.21 EPS. Astrazeneca PLC’s revenue for the quarter was down 4.0% on a year-over-year basis. On average, equities research analysts expect that Astrazeneca PLC will post $2.97 EPS for the current year.

The company also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were paid a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock valued at $65,485,000 after buying an additional 6,027 shares during the last quarter. Integrated Investment Consultants LLC raised its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock valued at $964,000 after buying an additional 1,027 shares during the last quarter. Fisher Asset Management LLC raised its position in Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock valued at $10,159,000 after buying an additional 105,570 shares during the last quarter. Finally, Stockman Asset Management raised its position in Astrazeneca PLC by 11.3% in the first quarter. Stockman Asset Management now owns 62,700 shares of the company’s stock valued at $1,766,000 after buying an additional 6,380 shares during the last quarter. 11.39% of the stock is owned by institutional investors.

About Astrazeneca PLC

Related posts

Leave a Comment